Metalmark Capital

Novel therapies to reboot cells and organs

Cell & Gene Therapy

Jasper Therapeutics develops therapeutics through the editing of mast cells and stem cells for the treatment of oncology, dermatology, anemia, hematology, auto-immune, and genetic diseases. The company’s therapeutics use the editing of cell mRNA and DNA to help overcome issues with regard to allogeneic and autologous gene-edited stem cell grafts. The company is listed on the Nasdaq and trades under the ticker symbol JSPR after a merger with Special Purpose Acquisition Company (SPAC) Amplitude Healthcare in May 2021. As of May 2024, the company had one therapeutic candidate, Briquilimab, which was being tested across multiple applications. For Mast Cell Diseases, Briquilimab was being tested for the treatment of Chronic Spontaneous Urticaria, Chronic Inducible Urticaria, and asthma. Its asthma application was in the preclinical stage, while its other two applications were in clinical testing phases. Briquilimab was also being tested for the treatment of two Stem Cell-related diseases, Low to Intermediate Risk Myelodysplastic Syndromes and Severe combined Immunodeficiency, both of which were in clinical testing phases. Jasper also had partner programs for treating Stem Cell-related diseases, testing Briquilimab for the treatment of Fanconi Anemia (in partnership with Stanford University), Sickle Cell Disease, Chronic Granulomatous Disease, and GATA2 MDS, all in partnership with the National Institute of Health.

Orgenesis is a provider of both cell-based therapies and gene-based therapies for the treatment of issues related to oncology, immunology, cariology, orthopedia, endocrinology. Specifically, the company develops therapeutics to treat cancer, genital warts, Covid-19, pancreatitis, liver, kidney and dermatological diseases, psoriasis, osteoarthritis, erectile dysfunction, musculoskeletal diseases, and acute and chronic kidney diseases. Orgenesis uses various technology models to develop its cell therapeutics, ranging from chimeric antigen receptor T cells, T cells, and natural killer cells. The company has commercialized two therapeutics that are used in clinical settings; Kyslecel for treatment of Chronic Pancreatitis and Cartil-S/Chondroseal for osteoarthritis. The company is listed on the Nasdaq and trades under the symbol ORGS.As of May 2024, the company had five immuno-oncology therapeutics in development, three therapeutics for viral diseases, two therapeutics for metabolic and autoimmune diseases, two therapeutics for vascular and musculoskeletal diseases, and two therapeutics for kidney diseases in various stages of clinical testing.Key customers and partnershipsOrgenesis formed a joint venture in April 2020 with a spin-off from Liege University in Belgium, RevaTis, (a biotechnology company) to further the development of autologous therapies. Through the partnership, RevaTis would build on its success in developing therapeutics to advance its candidate’s testing to human trials by using Orgenesis’s expertise and technology.Furthermore, in January 2022, the company partnered with Johns Hopkins to create the Maryland Center for Cell Therapy Manufacturing. The center was developed to manufacture cell and gene therapeutics which could be then used to treat patients being treated at Johns Hopkins.Orgenesis partnered with the University of California, Davis in June 2023 to boost access to gene and cell therapies in California. Through the partnership, Orgenesis Mobile Processing Units and Labs would be rolled out at multiple locations within the university grounds to provide on-site development and manufacturing of cell and gene therapies to help increase access to such therapies while reducing costs.In April 2024, the company announced that Orgenesis and Germfree, a modular cleanroom infrastructure and service provider, had signed an asset purchase and strategic partnership agreement. Through the partnership, Germfree would combine its expertise and manufacturing facility environments with Orgenesis’ processes and analytical development capabilities to reduce the production costs of cell and gene therapy products.

Morgenesis is a subsidiary of Orgenesis, and it provides point-of-care services.

Orgenesis is a development stage company with a novel therapeutic approach in the treatment of diabetes by correcting malfunctioning organs with new functional tissues created from the patient’s own existing organs. Orgenesis employs a molecular and cellular approach directed at converting liver cells into functional insulin-producing cells as a treatment for diabetes. This new therapeutic approach is called Autologous Insulin Producing (AIP) cell transplantation.  Beta cell replacement is one of the most promising approaches for treatment of Insulin Dependent Diabetes Mellitus (IDDM). Currently, pancreas islet transplantation is the only approved cell replacement technology and it's the best available treatment for diabetics. However, it's impractical because of a shortage of donor tissue and rejection rate by the patient' immune system. Orgenesis believes that converting the diabetic patients own tissue to insulin producing cells will overcome the problem of donor shortage. Moreover, since the diabetic patient serves as his/her own donor, there is no risk of transplant rejection.  Orgenesis has manifested promising results in in-vitro and in-vivo studies using human liver tissues. Based on this significant discovery and these findings, Orgenesis has designed an efficient and clear work-plan to initiate clinical testing in the next few months allowing the company to launch phase I clinical trials following FDA guidelines followed by the launch of Phase II clinical trials within a year.

Innovetive Petcare owns and operates veterinary hospitals across the country. Their clinics benefit from tools, resources, and a great support team dedicated to helping veterinary practices prosper and grow.  Innovetive Petcare runs a great business so veterinarians can focus on providing exceptional patient care.  They want veterinarians and staff to enjoy a better life, with more work-life balance, a strong supportive community, and ongoing training and career development.

Jasper is a biotechnology company focused on enabling safer conditioning agents to allow for the expanded use of curative therapy with stem cell transplants and gene therapies. The company s novel engineered hematopoietic stem cells (eHSCs) platform aims to overcome the limitations of transplant grafts while also unlocking the potential of stem cells, potentially increasing the number of patients who could benefit from allogeneic and autologous gene-edited hematopoietic stem cell therapy. Jasper’s lead compound, JSP191, is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients undergoing a stem cell transplant.

Northeast Natural Energy is a producer of natural gas. Its dedication to precise, focused science and engineering enables it to create the best wells available, and its persistence in the basin through the most difficult conditions has allowed it to build trust with its neighbors. Northeast Natural Energy is committed to achieving energy independence by producing efficient, affordable domestic natural gas.

Premier Research is a biotech startup that helps biopharmaceutical and medical device companies bring their developments. Premier Research's deep, focused expertise targets the therapeutic areas and indications where today’s biotech and specialty pharma pioneers are doing the most amazing work. The company is composed of 1,000 employees strong and operate in more than 20 countries, delivering unmatched expertise, operational skills, and dedication to meeting customers’ most challenging needs.

Valagro is a global leader in the production and commercialization of biostimulants and specialty nutrients for use in agricultural production, lawns, gardening and various industrial applications. Valagro also produces special ingredients for animal feed, human food and cosmetics. The Company was founded in 1980 in Abruzzo, Italy, and currently has 13 subsidiaries located throughout the world with over 600 employees. In addition to its production site and R&D center in Atessa, Italy, the company has two other active production facilities in Norway and three others in India. Valagro most recently acquired the Indian company SriBio in 2015, which is recognized for its contribution to the development of environmentally-friendly and sustainable biological solutions in agriculture. Valagro’s distribution network currently reaches over 80 countries.

Reliance Gathering is a crude oil gathering affiliate of Permian Basin-focused Reliance Energy. Reliance is a private Midland based oil and gas company focused on developing upstream and midstream assets. The Company has over 100,000 net acres in the Permian Basin, including approximately 40,000 net acres in the prolific Northern Midland Basin.

Sebela Pharmaceuticals is committed to improving patients’ lives by developing, marketing and selling differentiated branded prescription pharmaceuticals for patients whose needs are not adequately satisfied. Sebela Pharmaceutical’s commercial activities are focused in the United States for niche therapeutic markets including gastroenterology, dermatology and women’s health. To fulfill our commitment to improving patient’s lives, we are continuing to grow our US commercial infrastructure, marketed product portfolio and late stage development pipeline in our core therapeutic areas. Our growth strategy includes in-licensing and acquiring late-stage drug candidates and marketed products that utilize and enhance our existing development and commercial capabilities.

PTW Energy Services offers fabrication, construction, and maintenance services.

Bostwick Laboratories provides anatomic and clinical pathology laboratory services specializing in the monitoring and diagnosis of cancer. Bostwick Laboratories is a leader in urologic anatomic pathology with expertise and a growing presence in the dermatology, gastroenterology, gynecology, nephrology and hematology sectors of the anatomic pathology market.

Triana Energy is an oil & energy company providing oil and gas exploration services.

Union Drilling provides contract land drilling services and equipment, primarily to natural gas producers in the U.S. Since commencing operations in 1997, They have increased the size of our fleet to 69 land drilling rigs, through a combination of acquisitions and new rig construction. Of these 69 rigs, 59 are marketed and ten are stacked. In the fourth quarter of 2005, they expect to take delivery of two newly constructed rigs, increasing the size of their fleet to 71 rigs.

Tenet Healthcare Corporation is one of the largest investor-owned health care delivery systems in the nation.

Cross Country Healthcare is a provider of staffing and workforce solutions for the healthcare sector. It offers services including temporary, permanent, and locum tenens placements, along with advisory services to meet labor-related challenges.

Cantera Resources, Inc. offers processing and marketing services for natural gas and liquids.

Metalmark Capital is a leading private equity firm established by the principals of Morgan Stanley Capital Partners (MSCP) to manage the Metalmark Capital and MSCP funds. Since 1986, the Metalmark Capital and MSCP funds have invested $7 billion of equity capital in over 100 companies. These companies span a broad range of industries, including their focus sectors: energy/natural resources, industrials and healthcare.

Metalmark Capital

Portfolio

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless